Literature DB >> 967201

Polycythemia vera: stem-cell and probable clonal origin of the disease.

J W Adamson, P J Fialkow, S Murphy, J F Prchal, L Steinmann.   

Abstract

Two women with polycythemia vera and heterozygosity (GdB/GdA) at the X-chromosome-linked locus for glucose-6-phosphate dehydrogenase were studied to determine the nature of the cellular origin of their polycythemia. In contrast to unaffected tissue, such as skin fibroblasts, which consisted of both B and A types, the glucose-6-phosphate dehydrogenase of the patients' erythrocytes, granulocytes and platelets was only of Type A. These results provide direct evidence for the stem-cell nature of polycythemia vera and strongly imply a clonal origin for this disease. The fact that no descendants of the presumed normal stem cells were found in circulation suggests that bone-marrow proliferation in this disorder is influenced by local (intramarrow) regulatory factors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 967201     DOI: 10.1056/NEJM197610212951702

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  106 in total

Review 1.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 2.  Clinical consequences of clonal hematopoiesis of indeterminate potential.

Authors:  David P Steensma
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Mitochondrial DNA spectra of single human CD34+ cells, T cells, B cells, and granulocytes.

Authors:  Yoji Ogasawara; Kazutaka Nakayama; Magdalena Tarnowka; J Philip McCoy; Sachiko Kajigaya; Barbara C Levin; Neal S Young
Journal:  Blood       Date:  2005-07-14       Impact factor: 22.113

4.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.

Authors:  Ross L Levine; Claude Belisle; Martha Wadleigh; David Zahrieh; Stephanie Lee; Pierre Chagnon; D Gary Gilliland; Lambert Busque
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

5.  Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.

Authors:  Alison R Moliterno; Donna M Williams; Ophelia Rogers; Jerry L Spivak
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

Review 6.  X-linked clonality testing: interpretation and limitations.

Authors:  George L Chen; Josef T Prchal
Journal:  Blood       Date:  2007-04-13       Impact factor: 22.113

Review 7.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

Review 8.  Clinical consequences of clonal hematopoiesis of indeterminate potential.

Authors:  David P Steensma
Journal:  Blood Adv       Date:  2018-11-27

9.  Activated phenotype in neutrophils and monocytes from patients with primary proliferative polycythaemia.

Authors:  N B Westwood; E R Copson; L A Page; A R Mire-Sluis; K A Brown; T C Pearson
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

Review 10.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.